Business
Positive results from FractalDx study published
Positive results from FractalDx study published.
About this update from Renalytix Plc
[{"type":"text","content":"\n \nRNS Number : 4557B Renalytix AI PLC 07 June 2019 \n\nRenalytix AI plc\n(\"RenalytixAI\" or the \"Company\")\n \nPositive results from FractalDx study published\n \nDemonstrates ability to predict early rejection in kidney transplant\nSupports successful development of a predictive blood test for transplant patients\n \nRenalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces positive study results have been published in the Journal of Clinical Investigation (JCI) Insight. These results show FractalDx portfolio technology can accurately predict early acute kidney rejection in transplant patients. Early detection of acute transplant rejection is a critical unmet medical need that directly effects transplant success and long-term patient survival. In addition, the published results suggest that FractalDx can be used to personalise and potentially optimise the administration of immunosuppression therapy in kidney transplant patients. This could mitigate toxic side effects and damage to the transplanted kidney arising from excessive dosing. \n \nLead investigator for the study was Dr. Barbara Murphy, Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai (ISMMS).\n \nDr. Christian P. Larsen, Professor of Surgery, Division of Transplantation, Department of Surgery at the Emory University School of Medicine and member of the RenalytixAI Kidney Transplant Advisory Board, said: \"This study offers the possibility to bring an individualised approach to the therapy selection for kidney transplant recipients, particularly in relation to selection of immunosuppression regimen. Current standard of care provides limited opportunity to identify patients most at risk of early acute rejection, and therefore the availability of a non-invasive blood test prior to transplant as presented in this publication, would represent a significant advance for the field.\" \n \nThe publication coincides with an oral presentation of key data from the study at the American Transplant Congress (ATC 2019), the Joint Annual Meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).2&...